NCT00189917已完成1 期
An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Occurrence, relationship and intensity of any serious adverse event at any time during the study.
研究概览
简要总结
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in populations with atopic disorders.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects
- •Read, signed and dated informed consent.
- •Women of childbearing potential must use an acceptable method of contraception
- •Group 1: Healthy subjects
- •No history of atopic dermatitis as documented in the patient file
- •No active atopic dermatitis
- •No other atopic disorders such as asthma or allergic rhinitis.
- •Prick test without clinical significance
- •IgE within normal range
- •Group 2: Subjects with history of atopic dermatitis
- •Group 3: Subjects with mild active atopic dermatitis
- •SCORAD 1 -
- •Group 4: Subjects with mild allergic rhinitis
- •At least one active allergic rhinitis phase during last year.
排除标准
- •Known or suspected history of smallpox vaccination or typical vaccinia scar.
- •Positive test result in MVA specific ELISA at screening.
- •Positive result in HIV or HCV antibody test at screening.
- •Surface antigen of Hepatitis B Virus (HBsAg) positive at screening.
- •Pregnant or breast-feeding women.
- •Positive pregnancy test at screening and/or within 24 hours prior to vaccination.
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the institutional upper limit of normal.
- •Positive urine glucose by dipstick or urine analysis.
- •Inadequate renal function defined as a serum creatinine above the institutional upper limit of normal; urine protein >30 mg/dl or trace proteinuria (by urine analysis or dipstick); and a calculated creatinine clearance <80 ml/min.
- •Electrocardiogram (ECG) with clinical significance.
- •Hemoglobin <11 g/dl; White blood cells less than 2,500 and more than 11,000/mm3; Platelets less than 140,000/mm
- •Uncontrolled serious infection i.e. not responding to antimicrobial therapy.
- •History of any serious medical condition, which in the opinion of the investigator would compromise the safety of the subject.
- •History of or active autoimmune disease.
- •Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment.
- •History of malignancy.
- •History or clinical manifestation of clinically significant mental illness or haematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders.
- •Any condition which might interfere with study objectives.
- •History of immunodeficiency.
- •History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or other heart condition under the care of a doctor.
- •Three or more of the following risk factors: High blood pressure, high blood cholesterol, diabetes mellitus or high blood sugar, a first degree relative who had a heart condition before the age of 50, smoking cigarettes.
- •History of chronic alcohol abuse and/or intravenous drug abuse.
- •History of allergic reactions likely to be exacerbated by any component of the vaccine.
- •History of anaphylaxis or severe allergic reaction.
- •Acute disease (illness with or without a fever) at the time of enrollment.
- •Any vaccinations within a period starting 30 days prior to administration of the vaccine and ending at study conclusion.
- •Chronic administration of immuno-suppressant or immune-modifying drugs.
- •Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy.
- •Administration or planned administration of immunoglobulins and/or any blood -- Use of any investigational or non-registered drug.
- •Blood donation 8 weeks in advance or during study participation.
研究组 & 干预措施
GP 1: healthy, no AD
Experimental
Healthy subjects without any history of, or current signs and symptoms of atopic disease, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
干预措施: IMVAMUNE (MVA-BN) (Biological)
GP2: prev. allerg. rhinitis
Experimental
Subjects having documentation of at least one allergic rhinitis event during the previous year, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
干预措施: IMVAMUNE (MVA-BN) (Biological)
GP3: history of AD
Experimental
Subjects having documentation of a history of Atopic Dermatitis, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
干预措施: IMVAMUNE (MVA-BN) (Biological)
GP4: active AD
Experimental
Subjects presenting active Atopic Dermatitis and having an individual SCORAD value between 1 and 15, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
干预措施: IMVAMUNE (MVA-BN) (Biological)
结局指标
主要结局
Occurrence, relationship and intensity of any serious adverse event at any time during the study.
次要结局
- ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points).
- Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points).
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected PatientsHIV InfectionsNCT00189904Bavarian Nordic151
Unknown
1 期
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy AdultsCoronavirus Disease (COVID-19)NCT04885361OSE Immunotherapeutics48
已完成
1 期
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast CancerMetastatic Breast CancerNCT00952692Michael Morse, MD12
已完成
1 期
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric CancerCLDN18.2-positive Gastric AdenocarcinomaCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of EsophagusNCT01671774Astellas Pharma Global Development, Inc.29
已完成
1 期
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary HistologyCarcinoma, Renal CellRenal Cell Carcinoma of Papillary HistologyRenal Cell Carcinoma With Clear Cell HistologyRenal Cell Carcinoma With Non-Clear Cell HistologyNCT01672775Agensys, Inc.34